This website is intended for Medical Professionals only. By using this site you confirm that you are a healthcare professional.

News
Early autism screening has limited effect Screening for autism at three years of age only identifies those ... (18 Jun 2019)
Research explores the impact of masculine ... Pressures and expectations of masculinity and a lack of ... (18 Jun 2019)
Schizophrenia: adolescence is the ... Schizophrenia causes hallucinations and memory or cognition ... (18 Jun 2019)
Atrial fibrillation linked to increased risk ... Atrial fibrillation (AF) is linked to an increased risk of ... (18 Jun 2019)
Study challenges “no pain no gain” ... Patients with peripheral arterial disease should be given the ... (18 Jun 2019)
Sunday, 08 April 2018 17:52

Benzodiazepines can help depression Featured

Rate this item
(0 votes)

A paper published in the current issue of Psychotherapy and Psychosomatics, as a result of the collaboration of several universities (University of Bologna, The Pennsylvania State University, Wayne State University, University of Pennsylvania) points to the important role that benzodiazepines may have in depression.

The aim of the study was to perform a systematic review and, when feasible, a meta-analysis of randomized controlled trials using benzodiazepines as a monotherapy versus placebo, antidepressant drugs, or both, in the treatment of adult patients with a primary diagnosis of depressive disorder or anxious depression.

A total of 38 studies met the criteria for inclusion in this study. Only 1 study concerned a newer antidepressant: fluvoxamine. For the meta-analysis, data on response rate included 22 randomized controlled trials, considering benzodiazepines versus placebo (8 comparisons) and benzodiazepines versus tricyclic antidepressants (TCA) (20 comparisons). Results showed a lack of significant differences as to response rate between benzodiazepines and placebo, as well as between benzodiazepines and tricyclic antidepressants. Analysis of individual studies disclosed that, in more than half of the studies comparing benzodiazepines to tricyclic antidepressants and/or placebo, benzodiazepines were significantly more effective than placebo and as effective as tricyclic antidepressants.

These findings highlight that benzodiazepines are a therapeutic option in anxious depression and there are no indications that antidepressant drugs are preferable. There is a pressing need for randomized controlled trials of adequate methodological quality and follow-up comparing benzodiazepines to second-generation antidepressants and placebo in anxious depression. Giovanni Fava, MD, the lead investigator of the study commented: “The data clearly indicate that benzodiazepines have a role in managing anxious and mild depression and present many advantages over antidepressants. The commercial war against benzodiazepines (due to their low cost) has inflated their dependence potential. Antidepressant drugs may be much worse.”


Full bibliographic information:
Benzodiazepines as a Monotherapy in Depressive Disorders: A Systematic Review. Psychother Psychosom 2018;87:65–74

Read 1255 times Last modified on Sunday, 08 April 2018 18:57

Latest news

Highlights

Join

Connect with other Medical Professionals on fb in a closed facebook group

Login

Top
We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…